Arnott C, Li Q, Kang A, et al. - In many trials, inhibition of sodium-glucose cotransporter 2 in patients with type 2 diabetes mellitus has afforded protective effects, however, uncertainty exists regarding the consistency of the cardiovascular benefits gained across patient subsets, so, researchers analyzed 4 large-scale trials that compared sodium-glucose cotransporter 2 inhibition vs placebo among patients with diabetes mellitus and described influences on cardiovascular outcomes overall and for participant subgroups defined at baseline by cardiovascular disease, decreased kidney function, and heart failure. Overall 38,723 patients with a mean 2.9 years of follow-up were included. In terms of hospitalization for heart failure, cardiovascular mortality, and mortality from any cause, benefits were seen in all patient subgroups. Findings revealed that in diverse subsets of patients suffering from type 2 diabetes mellitus, treatment with sodium-glucose cotransporter 2 inhibitors afforded protection against cardiovascular disease and death, irrespective of cardiovascular disease history.